FDA Grants Supplemental Approval to AstraZeneca's Calquence

Date : 11/21/2019 @ 4:43PM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 50.17  1.23 (2.51%) @ 1:00AM
After Hours
Last Trade
Last $ 50.17 ◊ 0.00 (0.00%)

FDA Grants Supplemental Approval to AstraZeneca's Calquence

AstraZeneca (NYSE:AZN)
Historical Stock Chart

6 Months : From Aug 2019 to Feb 2020

Click Here for more AstraZeneca Charts.

By Michael Dabaie


The U.S. Food and Drug Administration granted supplemental approval to AstraZeneca PLC (AZN) for Calquence to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy, the FDA said.

The FDA said the approval was part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada. Project Orbis provides a framework for concurrent submission and review of oncology drug applications among the FDA's international partners.

AstraZeneca ADRs were recently up 1% to $47.47.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

November 21, 2019 11:28 ET (16:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.